Advocacy – Page 6 – Muscular Dystrophy Canada

Muscular Dystrophy Canada and Independent Living Canada partner to help lead the development of Canada’s first ever Disability Inclusion Action Plan

FOR IMMEDIATE RELEASE

Toronto, ON – January 27, 2021 – Muscular Dystrophy Canada (MDC) and Independent Living Canada (IL Canada) are partnering to equitably consult with individuals, organizations and stakeholders across disabilities to help inform the development of Canada’s first Disability Inclusion Action Plan (DIAP).

Beginning in January 2022, this 15-month collaboration will both inform the development of the DIAP in advance of its release, and continue to assess and improve the Plan throughout its implementation. The DIAP will focus on reducing poverty among persons with disabilities, getting more persons with disabilities employment opportunities, and realizing the goal of the Accessible Canada Act to achieve a barrier-free Canada by 2040, making it easier for persons with disabilities to access federal programs and services and fostering a culture of inclusion. Our goal is to ensure all Canadians have the opportunity to provide feedback, express concerns, and share their experiences to make this vital action plan as inclusive and impactful as possible.

With over 100 disability organizations invited to collaborate on this engagement process, IL Canada and MDC were selected to co-lead this project with support and funding from Employment and Social Development Canada (ESDC).

“For The Disability Action Plan to make a real impact in the lives of persons with disabilities, it has to be informed by lived experience. I’m grateful that Muscular Dystrophy Canada and Independent Living Canada will be working with the disability community to determine what barriers are still preventing persons with disabilities from participating in society, and how Canada can remove them to create a more equal, inclusive, and prosperous country” says The Honourable Carla Qualtrough, Minister of Employment, Workforce Development and Disability Inclusion.

IL Canada and MDC look forward to leading this process while ensuring representation from within all areas of disability, including racialized and LGBTQ2S+ communities.

“Independent Living Canada is thrilled to be leading this consultation process in partnership with Muscular Dystrophy Canada, the pillar leads, and individuals affected by disabilities from coast-to-coast to coast. This is a once-in-a-lifetime opportunity to ensure that the voices of marginalized and hard-to-reach people affected by disabilities are provided the opportunity to have their voices heard about what should be included in the first-ever federal Disability Inclusion Action Plan,” says Anne MacRae, National Executive Director, Independent Living Canada.

“Muscular Dystrophy Canada is honoured to work in partnership with IL Canada to consult Canadians affected by disabilities and share these experiences in a method that will drive the implementation of the much needed Disability Inclusion Action Plan,” says Stacey Lintern, CEO, Muscular Dystrophy Canada. “This is a vital action plan which will impact each and every Canadian in some way. We look forward to expanding our person-centred approach and ensuring all voices are heard throughout this process.”

MDC and IL Canada look forward to working with Inclusion Canada, Canadian Council on Rehabilitation and Work, Canadian Association of the Deaf, and Eviance who have been designated as leads for the four respective thematic pillars of the DIAP: Financial Security, Employment, Accessible and Inclusive Communities and a Modern Approach to Disability.

“At Inclusion Canada we are extremely excited about hearing from persons with a disability, their representative organizations and stakeholders across the country as the lead on the financial security pillar of the Disability Inclusion Action Plan,” says Krista Carr, Executive Vice-President, Inclusion Canada. “Hundreds of thousands of people with disabilities in Canada live in poverty and this urgently needs to change. We are looking forward to getting started right away.”

“We are pleased and excited at the funding support for this project. We really look forward to working with our partner organizations in building new bridges to hard-to-reach components of the Deaf, Deaf-blind and disabled communities across Canada,” says Jim Roots, Executive Director, Canadian Association of the Deaf.

“The Canadian Council on Rehabilitation and Work (CCRW) recognizes the capability of persons with disabilities, and supports their choices for equitable and meaningful participation in work. We are proud to be a pillar of change and build up the community by sharing our values, knowledge and commitment to Disability Inclusion and ensuring that there is an equitable approach to disability inclusive design,” says Maureen Haan, President and CEO, CCRW. “We are honoured to be involved in the development of the DIAP as the lead agency of the Employment Pillar. We are excited and motived to ensure this project will bring change and a voice to those with lived experience that remain hard-to-reach and marginalized populations with disabilities.”

“Eviance looks forward to collaborating on this important piece of work, and bringing together the knowledge and diverse experiences of persons with disabilities, to strengthen the federal Disability Inclusion Action Plan,” says Dr. Susan L. Hardie, PhD, Executive Director, Eviance.

About Muscular Dystrophy Canada

Muscular Dystrophy Canada’s mission is to enhance the lives of those affected with neuromuscular disorders by continually working to provide ongoing support and resources while relentlessly searching for a cure through well-funded research. To learn more about Muscular Dystrophy Canada, please explore our website at muscle.ca or call our toll-free number at 1-800-567-2873.

About Independent Living (IL) Canada

Founded in 1986, Independent Living Canada is a national non-profit association of Independent Living Centres led by and for people with disabilities who promote the Independent Living Philosophy. IL Canada supports the development of Independent Living Centres, and provides education and leadership for its member organizations, partners and communities.

– 30 –

Media Contact

Heather Rice
Director, Marketing and Communications
Muscular Dystrophy Canada
heather.rice@muscle.ca
902-440-3714

AccessAbility Program to increase disability and inclusion education in classrooms

FOR IMMEDIATE RELEASE

November 17, 2021 – Today, International Student’s Day, Muscular Dystrophy Canada (MDC) is grateful to announce that Canada Post Community Foundation has provided $25,000 in funding to support an AccessAbility program. This program aims to shift the classroom setting by incorporating information and resources on disabilities, accessibility, inclusion and equity.

MDC’s AccessAbility program will focus on providing information for students and educators about living with a neuromuscular disorder (NMD), how to support individuals affected by a NMD and the development of a digital storybook through which students can share their personal neuromuscular stories.
While the majority of children and youth affected by NMDs have a physical disability, they can also experience sensory, development, hearing and learning disabilities. The unfortunate reality is that a large percentage of students who have disabilities feel like they do not fit in with their peers. This program will educate teachers and peers about living with a neuromuscular disorders while creating a more equitable and inclusive environment for children and youth affected.

“The information that will be shared with students, teachers and staff through the AccessAbility program will make a tremendous difference to increasing inclusion in Canadian schools,” shares Stacey Lintern, CEO, Muscular Dystrophy Canada. “MDC’s hope is for all students and educational staff to feel comfortable, accepted, and fully participate in their learning environment. Thanks to the generous support from the Canada Post Community Foundation, we are one step closer to making this the new reality.”

“The Canada Post Community Foundation is proud to help organizations that are working hard to make a difference in the lives of Canadian children and youth,” said Doug Ettinger, Canada Post President and CEO. “Through the generosity of our customers during our annual campaign, we’re able to fund incredible organizations that are focused on the complex and growing needs of young people in communities across the country.”

About Muscular Dystrophy Canada

Muscular Dystrophy Canada’s mission is to enhance the lives of those affected with neuromuscular disorders by continually working to provide ongoing support and resources while relentlessly searching for a cure through well-funded research. To learn more about Muscular Dystrophy Canada, please explore our website muscle.ca or call our toll-free number at 1-800-567-2873.

About the Canada Post Community Foundation

The Canada Post Community Foundation provides grants to Canadian schools, charities and organizations in an effort to make a difference in the lives of children across the country. It supports the small, underfunded projects that often go unnoticed, from coast to coast to coast. Through its grassroots, community-based approach, the Foundation plays a critical role in helping Canada Post achieve its purpose of A Stronger Canada – Delivered. To learn more about the Foundation, visit canadapost.ca/community.

– 30 –

For more information:

Heather Rice
Director, Marketing and Communications
Muscular Dystrophy Canad
Heather.Rice@muscle.ca
902-440-3714

Muscular Dystrophy Canada joins forces internationally to impact greater change at home

October 22, 2021 – Muscular Dystrophy Canada has signed a Statement of Intent with Muscular Dystrophy UK, Muscular Dystrophy Australia and Muscular Dystrophy Foundation of South Africa to help break down barriers for individuals living with neuromuscular disorders, worldwide.

“Our organizations share similar missions and values, and face similar challenges and hurdles. By coming together, we hope to share insights, policies and training to have a greater impact on the neuromuscular communities we support,” said Stacey Lintern, CEO, Muscular Dystrophy Canada.

The organizations recognize the need to work more actively on equality, diversity, inclusion and accessibility issues, and hope that more organizations will join them in the future.

“By working together on these issues, and sharing learnings with our partners, MDC will be able to more effectively and efficiently create sustainable change here in Canada, and play a role internationally,” added Lintern. “It has been an incredible experience working with these organizations thus far, and I have no doubt that our combined expertise and knowledge will result in positive changes for neuromuscular communities in the near future.”

ABOUT MUSCULAR DYSTROPHY CANADA

FOR MORE INFORMATION CONTACT:

Heather Rice
heather.rice@muscle.ca
902-440-3714

Recognizing dedication and passion beyond measure

Muscular Dystrophy Canada (MDC) recognizes and celebrates the contributions of individuals and groups who champion our mission with courage, determination, and passion through the Dr. David Green Awards Program. We are excited to announce the list of our esteemed 2021 award winners. These individuals show extraordinary commitment to raising funds, increasing awareness and advocating for the NMD community, supporting continued research, engaging other community members and building positive connections.

The type of compassion and leadership recognized by these awards is personified in Dr. Colleen O’Connell, MDC’s 2021 recipient of the Outstanding Healthcare Partner award. This award is presented to a physician or clinician for outstanding achievements in improving neuromuscular disorder clinical practice and/or who has played a major or lasting role in improving the quality of life of people affected by neuromuscular disorders and their families.

In the past year, Dr. O’Connell has supported MDC’s knowledge sharing and advocacy initiatives. Particularly, Dr. O’Connell supported MDC with gathering and sharing credible and timely information regarding COVID-19 and NMDs. She has advocated on behalf of patients with NMDs to receive prioritization for vaccination. She also presented at our #LetsTalkNMD webinars, and most recently, she is the chair of transition of care in DMD for an upcoming Duchenne conference. She has supported MDC in many ways and is exceptionally knowledgeable, available and willing to support the NMD community in Canada.

“MDC is incredibly grateful to have so many groups and individuals dedicated to supporting our mission and the NMD community as a whole,” says Stacey Lintern, CEO of Muscular Dystrophy Canada. “From giving their time, contributing innovative ideas, sharing their experiences and helping to advance MDC forward in all areas of our Mission efforts, volunteers are the back-bone of our organization. Thank you doesn’t even begin to cover just how appreciative we are of each and every one of you”.

We are so lucky to have such an amazing group of supporters, including Dr. O’Connell, who continue to support our Mission, challenge us to be better and unite the neuromuscular disorder community. Click here to learn more and see a full list of this year’s award winners.

2021 Award Winners

National collaboration awards funding for newborn screening in spinal muscular atrophy (SMA)

SMA is the leading cause of genetic infant death.
Early diagnosis is imperative to halt irreversible motor neuron loss and disease progression.
More than $700,000 awarded to projects across three provinces.

Toronto, ON, July 21, 2021 – Muscular Dystrophy Canada (MDC) today announced funding for newborn screening projects focused on spinal muscular atrophy from Alberta, Manitoba and Quebec. These are the first applicants to be awarded funds as part of a collaboration with Novartis Pharmaceuticals Canada Inc. (Novartis). This multi-year initiative will see up to $2 million invested, as well as ongoing support for the generation of critical evidence and best-practices to help make newborn screening for SMA a national reality.

“In a neuromuscular disorder like SMA, where time is of the essence, early diagnosis and prompt access to treatments are critical to achieving the best possible outcomes. Unfortunately, this is not the reality for most Canadian children born with SMA,” said Stacey Lintern, CEO, Muscular Dystrophy Canada. “With today’s announcement and the unparalleled commitment of government leaders, Novartis, the SMA community and MDC’s dedicated Board of Directors, Fire Fighters, clients, donors and supporters, we are one step closer to ensuring all Canadian newborns are screened for SMA.”

Newborn screening is a test done for babies shortly after birth to look for treatable diseases that usually show no symptoms in the newborn period. While Ontario is currently the only province to screen for SMA, MDC’s goal is to have the disorder added to all provincial newborn screening panels across Canada.

“As the mother of an infant with SMA who was not screened at birth, I know first-hand the devastating implications of delayed diagnosis,” said Laura Van Doormaal, Newborn Screening Advisory Committee member. “Today’s announcement means that one day soon, no matter where they live all families will have the opportunity to make critical healthcare decisions and realize their child’s full developmental potential from the very beginning.”

In order to ensure an evidence-based approach to funding, MDC and Novartis commissioned a readiness assessment to evaluate the feasibility of adding SMA to all provincial and territorial screening panels. Proposals were then evaluated by an independent international peer review committee under MDC’s guidance. Funded projects include pilot programs and the mapping of post-diagnosis referral pathways. Further details on the needs and readiness assessment, project selection, peer review and community advisory committees can be found here: muscle.ca/newborn-screening

“Our collaboration with Muscular Dystrophy Canada truly exemplifies the Novartis purpose of improving and extending patients’ lives,” said Andrea Marazzi Country Head, Novartis Pharmaceuticals Canada. “We’re honoured to partner on work that will bring lasting impact to the SMA community and healthcare systems across Canada. Time to diagnosis is crucial in SMA and we applaud the first round of funding recipients and all engaged provinces for their commitment to prioritize screening at birth.”

MDC will continue to work with British Columbia, Saskatchewan and the Maritimes to accelerate newborn screening for SMA coast-to-coast. Future phases of the national collaboration will include additional project funding, evaluation of projects and knowledge transfer, and exchange with stakeholders to ensure policy adoption across all provinces and territories.

About Muscular Dystrophy Canada

-30-

For more information:

Heather Rice
heather.rice@muscle.ca
902-440-3714

Call for Project Proposals: Newborn Screening for Spinal Muscular Atrophy in Canada

Today, we are excited to be launching Phase 2 of our work with a call for funding proposals for local NBS for SMA initiatives. It is anticipated that these projects will focus on the setting up of laboratories for testing and/or ensuring efficient uptake of the policy itself. An independent selection committee will review applications in the coming weeks and we expect to announce the first round of funding at the end of June.

LEARN MORE

Reduce the timing between doses for patients with neuromuscular diseases

Jurisdictions across the country have been following National Advisory Committee on Immunization (NACI) recommendation to put off second doses and prolong the time between the first and second doses of two-shot COVID-19 vaccines to up to four months. However, persons with neuromuscular disorders may have respiratory involvement, require immunotherapy and are particularly vulnerable to severe and life-threatening effects from contracting COVID-19 infection. Partial protection for some of the most vulnerable and high-risk patients in the country from this devastating disease is not acceptable, particularly as the virus and variants surge across the country. Together with neurologists, the Neuromuscular Disease Network for Canada, Jesse’s Journey and GBS-CIDP Canada, MDC submitted a letter to Health Minister Patty Hajdu, Dr. Quach-Thanh, Chair of NACI and each provincial health minister urging them to further nuance the list of those who should be prioritized for their second dose by including adults affected by neuromuscular disease.

If need any support accessing your first and/or second dose of the COVID-19 vaccine, please feel free to contact advocacy@muscle.ca.

Open letter to Health Minister Patty Hadju
Open letter to NACI

MDC Change Agents

As we celebrate National Volunteer Week, we are happy to share that the following members for MDC’s Advocacy Advisory Committee have been selected:

Catherine Boivin
Quebec
Profession: Digital Technologies Specialist and Consultant
Connection to MDC: Adult affected by a NMD

Alfred Breton-Pare
Quebec
Profession: Senior CRA; Project Manager; Clinical Research Manager
Connection to MDC: Parent of a child affected by a NMD, MDC Board Member

Emily Hong-Wing Chan, BSc (Hons), MSW (Cand.)
Ontario
Profession: Social Worker
Connection to MDC: Adult affected by a NMD

Dr. Sue Dojeiji MD, Med, FRCPC
Ontario
Profession: Physiatrist-in-Chief, Clinical educator; Neuromuscular Researcher
Connection to MDC: NMD Clinician-Scientist

Susan Jahnke
British Columbia
Profession: Business Owner & Website Manager
Connection to MDC: Adult affected by a NMD

Corrine Kagan, BA (Hons)
Ontario
Profession: Past Senior Program Director (ABI)
Connection to MDC: Adult affected by a NMD

Dr. Colin Kovacs, MD, Med, FRCPC
Ontario
Profession: Family Medicine/HIV Primary Care Physician; Assistant Professor in Internal Medicine at U of T
Connection to MDC: Adult affected by a NMD, Member of NMD4C

Ken Kramer, Q.C.
British Columbia
Profession: Principal & Senior Associate Counsel at KMK Law
Connection to MDC: Adult affected by a NMD

Louis Joseph Lauziere
Ontario
Profession: Past Senior Policy Advisor in Dept of Justice at Gov of Saskatchewan
Connection to MDC: Adult affected by a NMD

Michael Low, JD
Alberta
Profession: Litigation Associate at Fasken Martineau DuMoulin LLP
Connection to MDC: Parent of a child affected by a NMD

Stefanie Marinich-Lee, LLB.
Ontario
Profession: Lawyer, Corporate HR
Connection to MDC: Adult affected by a NMD

Erin Novakowski
Alberta
Profession: Undergraduate student at U of Alberta; Disability Social Media manager; Writer and Contributor for Accessible Housing Canada
Connection to MDC: Adult affected by a NMD

Thu Parmar, B.Sc. Pharm
Alberta
Profession: Clinical Pharmacist; Managed public drug programs at Alberta MoH; Senior Manager of Government Relations & Public Policy at Hoffmann-La Roche Limited (Roche Canada)
Connection to MDC: NMD Industry Partner

Jalee Pelissier
Ontario
Profession: PT/OT Aide
Connection to MDC: Adult affected by a NMD

Kara Reid, BSc OT
New Brunswick
Profession: Occupational Therapist
Connection to MDC: Member of Neuromuscular Clinic, MDC Board Member

Dr. Kerri Schellenberg MD, MMedEd, FRCPC, CSCN (EMG)
Saskatchewan
Profession: Neurologist and Medical Director ALS Clinic; Neuromuscular researcher.
Connection to MDC: NMD Clinician-Scientist

Erica Vella, BA
Ontario
Profession: Digital Broadcast Journalist with Global News Toronto
Connection to MDC: Family member of an adult affected by NMD

Fatima Vido-Vecchio, B.Sc. PT
British Columbia
Profession: Physiotherapist
Connection to MDC: Member of Neuromuscular Clinic

Elaine Whitmore
Ontario
Profession: Past CEO of John McGivney Children’s Centre
Connection to MDC: Friend of persons affected by NMD; Advocate

We are thankful to all who applied and applaud our new members for coming forward to help us work together towards inclusive policies that reflects and respects Canada’s diversity, values the neuromuscular experience and are accessibility-focused.

We look forward to influencing positive change together! If you have any questions about advocacy, please email advocacy@muscle.ca

Researchers from across Canada join The Tenaquip Foundation’s Walk4MD to raise awareness and funding for neuromuscular disorder community

FOR IMMEDIATE RELEASE April 15, 2021

Toronto, Ontario – For the second year in a row, Muscular Dystrophy Canada (MDC) is bringing the neuromuscular disorder (NMD) community together virtually for its annual Walk4MD, which raises much needed funds to support Canadians affected – and this year researchers are joining the Walk4MD family.

On June 19 at 3 p.m. EST, thousands of Canadians including six prominent NMD researchers across the country will come together, virtually, to participate in The Tenaquip Foundation’s Walk for Muscular Dystrophy (Walk4MD).

Dr. Reshma Amin from the Hospital for Sick Children in Toronto is excited to be one of the Walk4MD Research Champions. “I look after so many amazing children with neuromuscular disease and their families. They deserve to be celebrated and what better way to do so than in partnership with MDC through the Walk4MD.”

“Important advancements are taking place in research right now, and we want to ensure that these advancements continue, and result in better treatments and ultimately a cure for neuromuscular disorders. We feel very fortunate to have the support of Dr. Reshma Amin, MD; Dr. Bernard Brais, MD, PhD; Dr. Nicolas Chrestian, MD; Dr. Robin Parks PhD; Dr. Gerald Pfeffer, MD, PhD; and Dr. Martine Tetreault, PhD and look forward to our NMD community getting to know these incredible individuals better,” said Stacey Lintern, CEO, Muscular Dystrophy Canada.

She added, “I’m also pleased to share that The Tenaquip Foundation is joining us again as title sponsor, and Global has returned as media sponsor for the second year in a row. Like us, they are committed to raising awareness and funds for the Canadian NMD community.”

The Tenaquip Foundation’s Walk4MD is a signature fundraising event for MDC that raises critical funds to support Canadians impacted by neuromuscular disorders. This year, due to the ongoing COVID-19 pandemic, the funds raised are more important than ever.

“There is still urgency to raise funds to meet the increased needs of our clients during this time,” says Lintern. “Like last year, we’ve had to cancel the majority of our fundraising events for the safety and well-being of our team and the NMD community. That unfortunately, has resulted in a 60 per cent decrease in revenue in our first quarter last year.”

The goal of The Tenaquip Foundation’s Walk4MD this year is to raise $870,000. These funds will be invested in services and programs, like equipment, and ensure MDC can meet the unique needs of the neuromuscular community while continuing to invest in research for better health outcomes for individuals impacted by neuromuscular disorders.

To learn more about The Tenaquip Foundation’s Walk4MD or to register for this exciting event, please visit walk4MD.ca

-30-

ABOUT MUSCULAR DYSTROPHY CANADA

Muscular Dystrophy Canada’s mission is to enhance the lives of those impacted with neuromuscular disorders by continually working to provide ongoing support and resources while relentlessly searching for a cure through well-funded research. To learn more about Muscular Dystrophy Canada, please visit muscle.ca or call our toll-free number at 1-800-567-2873.

MEDIA CONTACT

Heather Rice
Muscular Dystrophy Canada
Heather.Rice@muscle.ca
902-440-3714

MDC’s Response to the CADTH and INESSS Recommendations for Onasemnogene abeparvovec: A Call for Newborn Screening

At the end of 2020, Health Canada approved Onasemnogene abeparvovec (Zolgensma®) for the treatment of pediatric patients with 5q Spinal Muscular Atrophy (SMA) with biallelic mutations in the SMN1 gene and three or fewer copies of SMN2 gene, or infantile-onset SMA, bringing renewed hope to Canadian families affected by SMA. Onasemnogene abeparvovec is the second treatment approved by Health Canada for SMA and the first gene therapy for SMA. The broad indication as part of Health Canada approval was followed up with recommendations from the Institut national d’excellence en santé et en services sociaux (INESSS) and most recently, the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committees. The recommendations were formulated following a comprehensive evidence-based review of the medication's efficacy or effectiveness and safety and an assessment of its cost-effectiveness. The CADTH recommendations note that Onasemnogene abeparvovec should be for patients who are: symptomatic or pre-symptomatic with one to three copies of the survival motor neuron gene; 6 months of age or younger; not currently requiring permanent feeding or ventilatory support (either invasive or non-invasive).

Based on the patient input we put forward to CADTH and INESSS, we know SMA contributes to a loss of independence, increased load on families, difficulty breathing, swallowing and loss of mobility and can have a negative impact on mental and emotional well-being. Since Health Canada’s approval of treatments for SMA, families have been anxiously approaching age limitations and tirelessly advocating for access. While we commend INESSS and CADTH for their thorough class reviews, we are disappointed to see Onasemnogene abeparvovec is not recommended for those over the age of 6 months and a case-by-case review mechanism has not been suggested by CADTH. This emphasizes the need for a comprehensive Rare Disease Strategy and a process/mechanism to address the evidence gap for older infants and children. We thank the clinical experts for contributing to the reviews and we are in full agreement with the clinical experts that “earliest possible initiation of therapy” is important when it comes to SMA because it is associated with irreversible loss of motor neurons and motor nerves. This means in order to best benefit from the treatments currently approved and available in Canada, a diagnosis should be available as early as possible. Thankfully, this is the case in Ontario – newborn screening for SMA is part of the infant screening panel at birth since 2020. However, for anyone outside of Ontario, a diagnosis prior to 6 months of age is not always achieved. The recent INESSS and CADTH recommendations highlight the critical need for newborn screening, especially in the presence of approved treatments, and strongly provides support for MDC’s current initiative to implement nation-wide newborn screening for SMA.

We acknowledge that the recent approval of another treatment for SMA and related drug review recommendations has taken us another significant step towards early diagnosis and treatment choice. MDC is committed to continually work with individuals affected by SMA and their families on an individualized basis to provide holistic supports, resources for making evidence-informed choices and supporting individual advocacy activities.

We are looking forward to continued research and developments that can demonstrate the meaningful benefits of early diagnosis and early access to treatments for health outcomes and health-related quality of life for Canadians affected by SMA.

Sincerely,
Stacey Lintern
Chief Executive Officer
Muscular Dystrophy Canada

Download this news article (PDF)